- Home
- PLRX vs KURA Comparison
PLRX vs KURA Comparison
Compare PLRX & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- KURA
- Stock Information
- Founded
- PLRX 2015
- KURA 2014
- Country
- PLRX United States
- KURA United States
- Employees
- PLRX N/A
- KURA N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLRX Health Care
- KURA Health Care
- Exchange
- PLRX Nasdaq
- KURA Nasdaq
- Market Cap
- PLRX 682.2M
- KURA 793.2M
- IPO Year
- PLRX 2020
- KURA N/A
- Fundamental
- Price
- PLRX $11.07
- KURA $7.39
- Analyst Decision
- PLRX Strong Buy
- KURA Strong Buy
- Analyst Count
- PLRX 7
- KURA 11
- Target Price
- PLRX $40.50
- KURA $27.89
- AVG Volume (30 Days)
- PLRX 544.0K
- KURA 1.5M
- Earning Date
- PLRX 02-26-2025
- KURA 02-25-2025
- Dividend Yield
- PLRX N/A
- KURA N/A
- EPS Growth
- PLRX N/A
- KURA N/A
- EPS
- PLRX N/A
- KURA N/A
- Revenue
- PLRX N/A
- KURA N/A
- Revenue This Year
- PLRX N/A
- KURA N/A
- Revenue Next Year
- PLRX N/A
- KURA $233.30
- P/E Ratio
- PLRX N/A
- KURA N/A
- Revenue Growth
- PLRX N/A
- KURA N/A
- 52 Week Low
- PLRX $10.22
- KURA $6.98
- 52 Week High
- PLRX $18.92
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- PLRX 36.41
- KURA 22.90
- Support Level
- PLRX $10.94
- KURA $7.02
- Resistance Level
- PLRX $12.70
- KURA $7.66
- Average True Range (ATR)
- PLRX 0.77
- KURA 0.33
- MACD
- PLRX -0.18
- KURA 0.10
- Stochastic Oscillator
- PLRX 4.69
- KURA 21.58
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.